Atazanavir News and Research

RSS
Atazanavir, also known as Reyataz, is a type of medicine called a protease inhibitor (PI). PIs block protease, a protein that HIV needs to make more copies of itself. Atazanavir was approved by the FDA on June 20, 2003, for use with other antiretroviral medication in the treatment of HIV infection. This medicine does
not cure or prevent HIV infection or AIDS and
does not reduce the risk of passing the virus to
other people.
Exploring molecular docking and molecular dynamics simulations as advanced tools for novel antiviral drug discovery

Exploring molecular docking and molecular dynamics simulations as advanced tools for novel antiviral drug discovery

In silico studies identify potent plant metabolites capable of inhibiting SARS-CoV-2

In silico studies identify potent plant metabolites capable of inhibiting SARS-CoV-2

Dolutegravir-based regimen more effective for treating pregnant people with HIV-1

Dolutegravir-based regimen more effective for treating pregnant people with HIV-1

HIV patients on antiretroviral treatment with protease inhibitors may have lower COVID-19 risk

HIV patients on antiretroviral treatment with protease inhibitors may have lower COVID-19 risk

Study finds atazanavir inhibits main SARS-CoV-2 protease

Study finds atazanavir inhibits main SARS-CoV-2 protease

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

Does interferon therapy work in COVID-19?

Does interferon therapy work in COVID-19?

New drug delivery system could be a boon for those on a multi-drug regimen

New drug delivery system could be a boon for those on a multi-drug regimen

Natural antioxidant bilirubin may provide cardiovascular benefits

Natural antioxidant bilirubin may provide cardiovascular benefits

New computational framework accurately predicts drug-drug and drug-food interactions

New computational framework accurately predicts drug-drug and drug-food interactions

FDA approves new treatment for all HCV genotypes 1-6

FDA approves new treatment for all HCV genotypes 1-6

FDA approves new combo drug Mavyret for adults with Hepatitis C infection

FDA approves new combo drug Mavyret for adults with Hepatitis C infection

ARV drug atazanavir may have significant effects on infant development

ARV drug atazanavir may have significant effects on infant development

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

MPP collaborates with University of Liverpool to accelerate development of HIV nanomedicines

MPP collaborates with University of Liverpool to accelerate development of HIV nanomedicines

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.